Particulars of Complaint One
Particulars 1, 2, 3, 4, 5, 7, 8, 9, 11, 15, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30 and 31 are relied upon as constituting unsatisfactory professional conduct for the purposes of section 139B(1)(a) individually or in any combination with the other particulars. Particulars 6, 10, 12, 13, 14, 16 and 29 are relied upon as constituting unsatisfactory professional conduct for the purposes of section 139B(1)(a) only in combination with other particulars.
All of the particulars are relied upon in the alternative, individually or in combination with other particulars, as other improper conduct for the purposes of section 139B(1)(l).
Patient A
- The practitioner's prescribing for Patient A of the Schedule 8 drug oxycodone between 14 October 2015 and 15 March 2018 as set out in Annexure A:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of oxycodone prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient A of the Schedule 4D drug diazepam between 14 October 2015 and 15 March 2018 as set out in Annexure A, when viewed together with the practitioner's prescribing for Patient A of the Schedule 8 drug oxycodone as set out in particular 1:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 34 of the PTGR
(b) otherwise was not clinically indicated or appropriate in the patient's circumstances,
having regard to the quantities of diazepam prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
- Between 25 April 2016 and 15 March 2018, the practitioner prescribed for Patient A the Schedule 8 drug oxycodone as set out in Annexure A in circumstances in which:
(a) oxycodone was a type C drug of addiction within the meaning of section 28(6) of the PTGA;
(b) by at least 13 April 2016, the practitioner held an opinion that Patient A was a drug dependent person; and
(c) the practitioner did not obtain the proper authority from the Secretary of NSW Health,
contrary to section 28(3) of the PTGA.
Patient B
- The practitioner's prescribing for Patient B of the Schedule 8 drug oxycodone between 13 February 2017 and 15 July 2018 as set out in Annexure B:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of oxycodone prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient B of the Schedule 4 drug quetiapine between 21 July 2016 and 2 September 2018 as set out in Annexure B:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 34 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of quetiapine prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient B of the Schedule 8 drug alprazolam between 13 February 2017 and 15 July 2018 as set out in Annexure B, when viewed together with the practitioner's prescribing for Patient B of the Schedule 8 drug oxycodone as set out in particular 4:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the dosages of alprazolam prescribed and the frequency and duration of prescribing by the practitioner.
- Between 8 June 2017 and 15 July 2018, the practitioner prescribed for Patient B the Schedule 8 drug oxycodone as set out in Annexure B in circumstances in which:
(a) oxycodone was a type C drug of addiction within the meaning of section 28(6) of the PTGA;
(b) by at least 8 June 2017, the practitioner held an opinion that Patient B was a drug dependent person; and
(c) the practitioner did not obtain the proper authority from the Secretary of NSW Health,
contrary to section 28(3) of the PTGA.
- Between 16 January 2016 and 16 July 2018, the practitioner prescribed for Patient B the Schedule 8 drug alprazolam as set out in Annexure B in circumstances in which:
(a) alprazolam was a type B drug of addiction within the meaning of section 28(6) of the PTGA and clause 123 of the PTGR;
(b) the alprazolam was for continuous therapeutic use by Patient B for a period exceeding two months; and
(c) the practitioner did not obtain the proper authority from the Secretary of NSW Health,
contrary to section 28(2) of the PTGA.
Patient C
- The practitioner's prescribing for Patient C of the Schedule 8 drug oxycodone between 24 October 2015 and 26 August 2018 as set out in Annexure C:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of oxycodone prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient C of the Schedule 4D drug diazepam between 24 August 2017 and 12 August 2018 as set out in Annexure C:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 34 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the frequency and duration of prescribing by the practitioner.
- Between 10 March 2018 and 26 August 2018 the practitioner prescribed for Patient C the Schedule 8 drug oxycodone as set out in Annexure C in circumstances in which:
(a) oxycodone was a type C drug of addiction within the meaning of section 28(6) of the PTGA;
(b) by at least 9 March 2018, the practitioner held an opinion that Patient C was a drug dependent person; and
(c) the practitioner did not obtain the proper authority from the Secretary of NSW Health,
contrary to section 28(3) of the PTGA.
Patient D
- The practitioner's prescribing for Patient D of the Schedule 8 drug oxycodone between 10 February 2017 and 3 September 2018 as set out in Annexure D:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of oxycodone prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient D of the Schedule 8 drug fentanyl between 3 December 2016 and 26 August 2018 as set out in Annexure D:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of fentanyl prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient D of the Schedule 4D drug diazepam between 1 April 2017 and 2 September 2018 as set out in Annexure D:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 34 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient D of the Schedule 4 drug methoxyflurane between 22 April 2017 and 5 September 2018 as set out in Annexure D:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 34 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the frequency and duration of prescribing by the practitioner.
- Between 22 July 2017 and 12 August 2018, the practitioner intramuscularly administered to Patient D or supervised the administration to Patient D of the Schedule 8 drug morphine as set out in Annexure D, where the duration and frequency of the administration:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances.
- Between 22 April 2017 and 5 September 2018, the practitioner prescribed for Patient D the Schedule 4 drug methoxyflurane as set out in Annexure D in circumstances in which:
(a) another medical practitioner at the Practice had referred Patient D to the Pain Clinic at St Vincent's Hospital Sydney ("Pain Clinic");
(b) on 6 October 2016, a Pain and Rehabilitation Registrar at the Pain Clinic had written to the other practitioner to the effect that, among other things, Patient D's ongoing use of methoxyflurane was not warranted;
(c) the practitioner was aware of that advice; and
(d) the practitioner was not familiar with methoxyflurane.
Patient E
- The practitioner's prescribing for Patient E of the Schedule 8 drugs oxycodone and oxycodone combined with naloxone (Targin), the Schedule 4D drugs clonazepam, temazepam, diazepam, nitrazepam and oxazepam, and the Schedule 4 drug tramadol, between 19 February 2016 and 30 August 2018 as set out in Annexure E, when viewed together with the narcotics (opioids) and benzodiazepines being prescribed for Patient E by her pain specialist:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of those drugs prescribed by the practitioner.
- The practitioner's prescribing for Patient E of the Schedule 8 drug oxycodone between 19 February 2016 and 30 August 2018 as set out in Annexure E, when viewed together with the narcotics (opioids) and benzodiazepines being prescribed for Patient E by her pain specialist:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the dosages of oxycodone prescribed and the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient E of the Schedule 8 drug oxycodone combined with naloxone (Targin) between 19 February 2016 and 30 August 2018 as set out in Annexure E, when viewed together with the narcotics (opioids) and benzodiazepines being prescribed for Patient E by her pain specialist:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the dosages of Targin prescribed and the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient E of the Schedule 4D drug diazepam between 29 October 2016 and 30 August 2018 as set out in Annexure E:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 34 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient E of the Schedule 4 drug tramadol between 27 April 2016 and 30 August 2018 as set out in Annexure E, when viewed together with the narcotics (opioids) and benzodiazepines being prescribed for Patient E by her pain specialist:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 34 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the dosages of tramadol prescribed and the frequency and duration of prescribing by the practitioner.
Patient F
- The practitioner's prescribing for Patient F of the Schedule 8 drug oxycodone between 13 April 2016 and 13 August 2018 as set out in Annexure F:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of oxycodone prescribed, the dosages prescribed and the frequency and duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient F of the Schedule 4D drug diazepam between 27 April 2016 and 14 June 2018 as set out in Annexure F, when viewed together with the other drugs that the practitioner was prescribing for Patient F:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 34 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances,
having regard to the quantities of diazepam prescribed and the duration of prescribing by the practitioner.
- Between 19 August 2018 and 3 September 2018, the practitioner prescribed for Patient F the Schedule 8 drug fentanyl as set out in Annexure F in dosages that, having regard to the oral Morphine Equivalent Daily Dose (oMEDD) of fentanyl being prescribed in comparison with the oxycodone it was replacing:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically appropriate in the patient's circumstances.
- Between 16 February 2017 and 13 August 2018, the practitioner prescribed for Patient F the Schedule 8 drug oxycodone as set out in Annexure F in circumstances in which:
(a) oxycodone was a type C drug of addiction within the meaning of section 28(6) of the PTGA;
(b) by at least 16 February 2017, the practitioner held an opinion that Patient F was a drug dependent person; and
(c) the practitioner did not obtain the proper authority from the Secretary of NSW Health,
contrary to section 28(3) of the PTGA.
- Between 13 April 2016 and 13 August 2018, the practitioner notated prescriptions of restricted drugs issued to Patient F with "Reg 24" (referring to regulation 24 of the National Health (Pharmaceutical Benefits) Regulations 1960 (Cth) ("PBS Regulations")) in circumstances in which:
(a) Patient F did not meet any of the circumstances specified in the PBS Regulations as permitting the supply of multiple repeats on one occasion; and
(b) it was not otherwise clinically indicated or appropriate to supply multiple repeats at one time to Patient F.
Patient G
- The practitioner's prescribing for Patient G of the Schedule 4D drug diazepam between 17 August 2017 and 2 September 2018 as set out in Annexure G:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 34 of the PTGR;
(b) otherwise was not clinically indicated or appropriate in the patient's circumstances,
having regard to the quantities of diazepam prescribed and the duration of prescribing by the practitioner.
- The practitioner's prescribing for Patient G of the Schedule 8 drug oxycodone between 21 January 2018 and 2 September 2018 as set out in Annexure G:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 79 of the PTGR;
(b) otherwise was not clinically indicated or appropriate in the patient's circumstances,
having regard to the duration of prescribing by the practitioner.
- On 2 February 2018, the practitioner prescribed for Patient G the Schedule 8 drug methadone as set out in Annexure G, which:
(a) did not accord with the recognised therapeutic standard of what was appropriate in the circumstances, contrary to clause 34 of the PTGR;
(b) otherwise was not clinically indicated or appropriate in the patient's circumstances.
- Between 21 January 2018 and 2 September 2018, the practitioner prescribed for Patient G the Schedule 8 drug oxycodone as set out in Annexure G in circumstances in which:
(a) oxycodone was a type C drug of addiction within the meaning of section 28(6) of the PTGA;
(b) by at least 14 October 2017, the practitioner held an opinion that Patient G was a drug dependent person; and
(c) the practitioner did not obtain the proper authority from the Secretary of NSW Health,
contrary to section 28(3) of the PTGA.